Clinical Trial Update: Dose Escalation Study of Clofarabine in Patients With Relapsed or Refractory Low Grade or Intermediate-Grade B-Cell Lymphoma [Phase 1]

View source ↗

Summary

This Phase 1 dose-escalation trial evaluated clofarabine in patients with relapsed or refractory low-grade or intermediate-grade B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• Clofarabine (Clolar) (clofarabine)

Snippet

Sponsor: Yale University | Conditions: B-Cell Lymphoma | Phase 1 | Status: COMPLETED